Leadership & People
Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Recent executive changes in the industry include C-suite moves at Bluebird Bio and Jounce Therapeutics. Meanwhile, new directors were appointed at Candel Therapeutics and Technoderma Medicines.
Kenny, a mainstay of our publications for three decades, has passed away in London.
Recent executive moves in the industry include C-suite changes at Amicus Therapeutics and Assembly Biosciences. Meanwhile, new directors were appointed at Torrent Pharmaceuticals and Perrigo, among others.
US drug pricing legislation that has picked up momentum could stymie R&D investment and curb the revenue tail for some big drugs, industry says, but CEOs also expect they can navigate the challenge.
Recent executive changes in the industry include C-suite changes at Herantis Pharma and MediGene. Meanwhile, new directors were appointed at Cyclerion Therapeutics and Allakos, among others.
Preparing for the eventual transition to an open commercial market for COVID-19 vaccines and treatments, Pfizer restructured its commercial team to incorporate the franchises.
Hal Barron is leaving just as GSK’s M&A firepower grows following the Haleon spin-out, but sounded a confident note about its potential blockbuster RSV vaccine candidate.
Recent executive changes in the industry include C-suite changes at Small Pharma and Nuvalent. Meanwhile, new directors were appointed at Alvotech and Versanis Bio, among others.
The Swiss drug maker is preparing for a smooth transition in 2023, appointing 20-year Roche veteran and diagnostic chief Thomas Schinecker as its next chief executive as Severin Schwan becomes chairman.
While the correction of the biotech markets downwards increases the chances of bolt-on deals, even with the reduced prices, interesting assets are not so easy to come by, so says Novartis CFO Harry Kirsch.
Inflation, rising interest rates, market volatility, violence in Ukraine and a persistent pandemic created a chaotic macroenvironment for doing business. Pharma appears poised to grow, nonetheless.
Recent executive changes in the industry include C-suite changes at SQZ Biotechnologies and Lineage Cell Therapeutics. Meanwhile, new directors were appointed at Piramal Pharma and Entasis Therapeutics, among others.
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.